This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sonus Networks, Novavax: Small-Cap Winner

NEW YORK ( TheStreet) -- Shares of Sonus Networks (SONS - Get Report) were zooming 26% to $3.78 on unusually high volumes Tuesday after it reported better-than-expected revenue growth and also forecast revenues above analyst expectations.

Revenue increased 21 percent to $83 million, from $68.7 million in the same period a year earlier, much higher than the $68.6 million analysts predicted. Sonus said its net income rose to $11.4 million from $10.3 million in the year-ago quarter. On a per share basis, earnings were flat at 4 cents as average shares outstanding increased in the 2010 period. Analysts surveyed by FactSet forecast earnings of 3 cents per share.

For 2011, Sonus said it expects revenue of $265 million to $285 million, higher than the $242.3 million analysts are currently expecting.

Novavax (NVAX - Get Report), which develops recombinant vaccines for infectious diseases, saw its shares rise 11% to $2.89 after it said it had been awarded a $179 million contract by the office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced clinical and manufacturing development of recombinant vaccines for the prevention of seasonal and pandemic influenza.

During the contract's 3-year base period, valued at $97 million, Novavax will develop and manufacture its clinical-stage, recombinant virus-like particle (VLP) influenza vaccines. The contract could be extended for an additional 24-month option period with $82 million in additional funding to build on the work Novavax accomplishes during the base period and to support manufacturing scale-up and licensure by the U.S. Food & Drug Administration.

Shares of KV Pharmaceuticals (KV-A) were soaring 7.6% to $8.73. The company said Tuesday that it had completed a private debt placement of $200 million, the proceeds of which will be used to repay debt obligations.

Endeavour Silver (EXK - Get Report) was gaining 8.7% to $8.06. Silver miners are in the spotlight as silver continued to outshine gold.

Shares of Pluristem Therapeutics (PSTI - Get Report) were up 6% to $2.62 after the company announced that a preclinical study demonstrating that the local administration of PLX cells following muscle injury resulted in a significant improvement in the recovery of muscle function when compared with the control group. WBB Securities initiated coverage on the stock with a "speculative buy".

Solar stocks Suntech Power (STP) and Yingli Energy (YGE - Get Report) were up about 4% each. Solar stocks fell on Monday after analyst reports indicated that a new draft being introduced this week in Italian parliament would cap solar installations at 8 gigawatts, and the cap would be implemented immediately and with no grandfathering clause.

--Written by Shanthi Bharatwaj in New York



>To contact the writer of this article, click here: Shanthi Bharatwaj.

>To follow the writer on Twitter, go to http://twitter.com/shavenk.

>To submit a news tip, send an email to: tips@thestreet.com.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
STP $0.53 0.00%
EXK $1.94 -2.02%
NVAX $8.07 -1.94%
PSTI $2.81 -2.09%
SONS $7.83 -0.63%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs